526PD - TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study

Y Nakamura,W Okamoto,T Kato,H Hasegawa,K Kato,S Iwasa,T Esaki,Y Komatsu,T Masuishi,T Nishina,S Nomura,M Fukui,S Matsuda,A Sato,S Fujii,J.I Odegaard,S Olsen,T Yoshino

doi:10.1093/annonc/mdz246.004

526PD - TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study

Y Nakamura, W Okamoto + Show 16 more

Open Access

https://doi.org/10.1093/annonc/mdz246.004

Copy DOI

Journal: Annals of Oncology	Publication Date: Oct 1, 2019
Citations: 32	License type: elsevier-specific: oa user license

Affiliation: National Cancer Center Hospital East, Shikoku Cancer Center, Hiroshima University Hospital, Osaka National Hospital, Aichi Cancer Center

#Research Grant #Funding Institution + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

526PD - TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study

Full Text